Memantine for Treatment-Resistant OCD
OCD is a chronic neuropsychiatric disorder that can cause significant psychosocial impairment (Goodman et al., 2021), and delay in treatment is associated with poor outcomes (Fineberg et al., 2015). Some patients with OCD do not respond to first and second-line treatment, so it is important to have the knowledge of available treatment options. Dr. David Osser gave an excellent clinically relevant 1-hour presentation on this topic in our Obsessive-Compulsive & Related Disorders Update 2021 Conference.
Augmentation with various glutamatergic agents is one of the options in treatment-resistant OCD management. Memantine is one of the agents with two randomized controlled trials (RCTs) showing the efficacy in OCD management as an augmentation agent:
Dr. David Osser gave the 2021 OCD treatment algorithm update for the Psychophramcology algorithm project at Harvard South Shore. This includes the evidence-informed recommendations considering efficacy, tolerability, safety, & patient preference.
Here is the list of topics included in his 1-hour presentation:
INTERESTED IN LEARNING MORE?
JOIN OBSESSIVE COMPULSIVE & RELATED DISORDERS UPDATE 2021 CONFERENCE:
